Vaccinex, Inc. (VCNX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Vaccinex, Inc. (VCNX) is down 22.3% since the beginning of the year. At $1 per share, VCNX is trading 44.3% below its 52-week high of $2. Investors who bought $1,000 worth of VCNX shares 5 years ago would now be looking at an investment worth $2.

Vaccinex, Inc. (VCNX) has returned -22.30% so far this year and 16.03% over the past 12 months.

Based on dividend-adjusted daily data since Aug 9, 2018, VCNX's average daily return is 0.00%, while the average monthly return is -4.38%.

Historically, 33% of months were positive and 67% were negative. The best month was Jul 2020 with a return of +75.4%, while the worst month was Dec 2024 at -74.1%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.

On a daily basis, VCNX closed higher 42% of trading days. The best single day was Oct 20, 2025 with a return of +104.2%, while the worst single day was Dec 17, 2024 at -61.4%.

Vaccinex, Inc. has an annualized alpha of -7.54%, beta of 0.55, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 10, 2018.

• This stock participated in 213.22% of S&P 500 Index downside but only -61.42% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.55 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

VCNX ranks 58 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Vaccinex, Inc. (VCNX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vaccinex, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vaccinex, Inc. was 99.99%, occurring on Nov 5, 2025. The portfolio has not yet recovered.

The current Vaccinex, Inc. drawdown is 99.97%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vaccinex, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vaccinex, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.